Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.8.0.1
Subsequent Events (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 01, 2017
member
$ / shares
shares
Oct. 31, 2017
$ / shares
shares
Oct. 03, 2017
$ / shares
shares
Sep. 30, 2017
shares
Jun. 30, 2017
shares
Jun. 28, 2017
shares
Nov. 13, 2017
USD ($)
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
Subsequent Event [Line Items]                      
Proceeds from exercise of warrants | $                 $ 800 $ 3,808 $ 0
Proceeds from issuance of common stock | $               $ 400      
Additional shares available for purchase                   160,000  
Weighted average exercise price, granted (in dollars per share) | $ / shares                   $ 2.14  
Series A Warrant                      
Subsequent Event [Line Items]                      
Number of warrants exercised (in shares)         12,250 1,295,995     500,739    
Subsequent Event                      
Subsequent Event [Line Items]                      
Weighted average exercise price, granted (in dollars per share) | $ / shares $ 1.95                    
Potential new members | member 2                    
Subsequent Event | Series A Warrant                      
Subsequent Event [Line Items]                      
Number of warrants exercised (in shares)             25,000        
Proceeds from exercise of warrants | $             $ 40        
Subsequent Event | Series A and Broker Warrants                      
Subsequent Event [Line Items]                      
Warrants outstanding (in shares)             420,000        
Subsequent Event | Executive Officers and Other Employees                      
Subsequent Event [Line Items]                      
Additional shares available for purchase     590,000                
Weighted average exercise price, granted (in dollars per share) | $ / shares     $ 2.49                
Subsequent Event | Chief Medical Officer                      
Subsequent Event [Line Items]                      
Additional shares available for purchase   75,000                  
Weighted average exercise price, granted (in dollars per share) | $ / shares   $ 1.92                  
Subsequent Event | Potential New Member of Science Advisory Board One                      
Subsequent Event [Line Items]                      
Additional shares available for purchase 10,000                    
Subsequent Event | Potential New Member of Science Advisory Board Two                      
Subsequent Event [Line Items]                      
Additional shares available for purchase 10,000                    
At Market Issuance Sales Agreement                      
Subsequent Event [Line Items]                      
Proceeds from issuance of common stock | $                   $ 400  
At Market Issuance Sales Agreement | Subsequent Event                      
Subsequent Event [Line Items]                      
Proceeds from issuance of common stock | $             $ 800        
Common Stock | At Market Issuance Sales Agreement                      
Subsequent Event [Line Items]                      
Number of shares sold       154,121              
Common Stock | At Market Issuance Sales Agreement | Subsequent Event                      
Subsequent Event [Line Items]                      
Number of shares sold             345,000        
Employee Stock Option | Subsequent Event                      
Subsequent Event [Line Items]                      
Term of awards 10 years                    
Vesting period 4 years                    
Employee Stock Option | Subsequent Event | Executive Officers and Other Employees                      
Subsequent Event [Line Items]                      
Term of awards     10 years                
Vesting period     4 years                
Employee Stock Option | Subsequent Event | Chief Medical Officer                      
Subsequent Event [Line Items]                      
Term of awards   10 years                  
Vesting period   4 years